Hence, targeting Zbtb16-Txnip-Trx2 pathway could serve as a novel therapeutic strategy for decreasing AF susceptibility in T2DM patients due to the important role in modulating ROS generation. Here, TXNIP is linked to type 2 diabetes mellitus.